Genmab (CPH:GEN)

QUOTE AND NEWS
GenEng News  Nov 24  Comment 
Genmab said it is halting a Phase III trial comparing the cancer drug ofatumumab, being co-developed with Novartis, to Roche’s rituximab in patients with follicular lymphoma. Genmab yesterday cited a planned interim analysis of data by the...
FierceBiotech  Nov 23  Comment 
Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.
Benzinga  Oct 25  Comment 
Genmab A/S (OTC: GNMSF) announced today it has achieved a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. (NYXE: JNJ), triggering a $3 million milestone payment. The milestone payment is for pre-clinical...
Benzinga  Oct 5  Comment 
Genmab A/S (OTC: GNMSF) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. (NYSE: JNJ), triggering a $3 million milestone payment. The milestone payment is for pre-clinical...
Benzinga  Sep 25  Comment 
Genmab A/S (OTC: GNMSF) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for daratumumab. The...
newratings.com  Sep 19  Comment 
BASEL (dpa-AFX) - Genmab A/S (GEN) announced the U.S. FDA has granted Priority Review to the supplemental Biologics License Application, or sBLA, for ofatumumab as maintenance therapy of patients with relapsed chronic lymphocytic leukemia. Genmab...
Benzinga  Sep 4  Comment 
Genmab A/S (OTC: GNMSF) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for daratumumab. The BLA is for daratumumab as a treatment for patients with multiple...





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki